Low-density lipoprotein (LDL) apheresis (LA) selectively eliminates lipoproteins containing apolipoprotein B 100 (ApoB100) on patients affected by severe dyslipidemia. In addition to lowering lipids, LA is thought to exert pleiotropic effects altering a number of other compounds associated with atherosclerosis, such as pro- and anti-inflammatory cytokines or pro-thrombotic factors.
Heparin-induced lipoprotein precipitation apheresis in dyslipidemic patients: A multiparametric assessment / Merolle, L; Marraccini, C; Latorrata, A; Quartieri, E; Farioli, D; Scarano, L; Fasano, T; Bergamini, S; Bellei, E; Monari, E; Tomasi, A; Di Bartolomeo, E; Baricchi, R; Pertinhez, Ta. - In: JOURNAL OF CLINICAL APHERESIS. - ISSN 1098-1101. - 35:3(2020), pp. 146-153. [10.1002/jca.21770]
Heparin-induced lipoprotein precipitation apheresis in dyslipidemic patients: A multiparametric assessment
Bergamini S;Bellei ESoftware
;Monari E;Tomasi A;
2020
Abstract
Low-density lipoprotein (LDL) apheresis (LA) selectively eliminates lipoproteins containing apolipoprotein B 100 (ApoB100) on patients affected by severe dyslipidemia. In addition to lowering lipids, LA is thought to exert pleiotropic effects altering a number of other compounds associated with atherosclerosis, such as pro- and anti-inflammatory cytokines or pro-thrombotic factors.File | Dimensione | Formato | |
---|---|---|---|
J Clin Apher_2020.pdf
Accesso riservato
Descrizione: Articolo principale
Tipologia:
Versione pubblicata dall'editore
Dimensione
1.68 MB
Formato
Adobe PDF
|
1.68 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris